Please Wait.....
Report
Europe Clinical Trials - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-08-01 I 75 Pages I Mordor Intelligence
Europe Clinical Trials Market Analysis
The Europe clinical trials market is valued at USD 23.59 billion in 2025 and is forecast to reach USD 32.99 billion by 2030, advancing at a 6.94% CAGR. Expansion rests on sustained pharmaceutical R&D investment, faster study start-up under the Clinical Trials Regulation, and wide adoption of decentralized and hybrid designs that lower patient-access barriers. Oncology programs keep capital flowing into late-stage studies, while neurology pipelines grow as Europe's population ages. Hybrid outsourcing models that blend large contract research organizations (CROs) with technology-enabled niche vendors help sponsors trim costs and shorten timelines. Competitive pressure from Asia-Pacific remains intense, yet Europe's regulatory reforms and deep investigator networks underpin a steady flow of high-value studies needed to retain global relevance.
Europe Clinical Trials Market Trends and Insights
High Pharmaceutical-Biotech R&D Intensity in Europe
Major multinationals have pledged more than EUR 2 billion of fresh investment across France, with Pfizer alone earmarking EUR 500 million to expand late-stage trials in hematology and rare cancers. Germany's Medical Research Act, effective 2025, allows parallel scientific and ethics reviews and permits confidential reimbursement talks that attract complex studies. Although European R&D spending still trails growth rates in the United States and China, policy makers are coupling tax credits with infrastructure grants to keep next-generation modalities-mRNA, cell, and gene therapies-onshore. Industry consolidation is speeding up as cash-strapped biotechs partner with CROs that already own pan-EU investigator networks. As a result, the Europe clinical trials market is witnessing more seamless, platform-based development programs that can move from Phase I through Phase III within integrated frameworks.
Rising Prevalence of Chronic & Infectious Diseases
An aging continent and lingering pandemic threats push demand for novel medicines, with more than 40 new products slated for German launch in 2025, most aimed at Alzheimer's disease, oncology, and genetic disorders. Oncology applications make up the largest share of submissions to the European Medicines Agency (EMA) pipeline, while vaccine and antiviral studies are leveraging compressed review timelines shaped during COVID-19. Digital biomarkers and home-based monitoring allow sponsors to integrate real-world data into study endpoints, raising recruitment efficiency among multimorbid patient pools. These factors collectively add buoyancy to the Europe clinical trials market even as recruitment grows more complex.
Stringent Multi-Layered Approval Processes
The ICH E6(R3) Good Clinical Practice guideline, effective July 2025, brings tougher data-integrity and computer-system-validation demands that lengthen sponsor checklists eca.de. National nuances in ethics-committee opinions generate unpredictable timelines, especially for digitally enabled or adaptive designs. Germany's new reporting duties for study participants add to monitoring overhead. These factors collectively suppress near-term growth even as harmonization efforts progress.
Other drivers and restraints analyzed in the detailed report include:
Growing Orphan-Drug Incentives & Rare-Disease Focus / ACT-EU & CTIS Accelerating Trial Start-Up Timelines / Europe's Falling Share of Global Patient Enrollment /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Phase III studies represented 53.22% of the Europe clinical trials market in 2024, confirming the region's role in confirmatory evidence generation. Sponsors leverage Europe's dense hospital networks and seasoned investigators to run pivotal oncology and immunology programs that feed EMA submissions. Adaptive Phase II designs, growing at a 7.93% CAGR, let companies kill or pivot assets sooner, a critical hedge against soaring development costs. Seamless II/III platforms and real-time analytics are blurring traditional phase boundaries, tightening cycle times, and reinforcing the Europe clinical trials market as a preferred venue for integrated programs.
Second-generation cell and gene therapies now benefit from EMA's advanced-therapy guidance, which allows conditional approvals supported by robust post-marketing data. The Europe clinical trials market size for Phase II work is projected to expand materially as sponsors align biomarker discovery with proof-of-concept studies. Post-authorization Phase IV programs are also growing because payers increasingly demand real-world evidence before green-lighting reimbursement.
Interventional designs accounted for 80.43% of the Europe clinical trials market size in 2024, underlining regulators' continued preference for randomized evidence. Adaptive designs are climbing at an 8.04% CAGR thanks to Bayesian statistics and interim-data modeling that support early futility stops and dose re-optimizations. Pragmatic and decentralized models are now acceptable under EMA guidance, broadening participation among rural and mobility-challenged patients.
Observational cohorts complement interventional work by harvesting long-term safety and comparative-effectiveness data from electronic health records. Master protocols, including umbrella and basket trials, reduce administrative duplication when sponsors test multiple drugs across biomarker subsets. Together, these methodologies keep the Europe clinical trials market agile amid rising cost pressures.
The Europe Clinical Trials Market Report is Segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Study Design (Diagnostic Radiology, and More), Service Type (Protocol Design & Feasibility, and More), Therapeutic Area (Oncology, and More), Sponsor Type (Pharmaceutical & Biopharmaceutical Companies, and More), and Geography (Germany, United Kingdom, and More). The Market Forecasts are Provided in Terms of Value (USD).
List of Companies Covered in this Report:
IQVIA / Parexel International (MA) Corporation / ICON / Thermo Fisher Scientific / LabCorp / Syneos Health / Medpace Holdings / Charles River / Clinipace / Eli Lilly and Company / Pfizer / Roche / Sanofi / Novo Nordisk / AstraZeneca / Boehringer Ingelheim / Novartis / Bayer / Johnson&Johnson / Merck /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Pharmaceutical-Biotech R&D Intensity In Europe
4.2.2 Rising Prevalence of Chronic & Infectious Diseases
4.2.3 Growing Orphan-Drug Incentives & Rare-Disease Focus
4.2.4 ACT-EU & CTIS Accelerating Trial Start-Up Timelines
4.2.5 Rapid Adoption of Decentralized / Hybrid Trial Models
4.2.6 Central & Eastern Europe's Cost-Efficient Patient Recruitment
4.3 Market Restraints
4.3.1 Stringent Multi-Layered Approval Processes
4.3.2 Lower Reimbursement Levels in Parts of Southern / CEE Europe
4.3.3 Europe's Falling Share of Global Patient Enrollment
4.3.4 Fragmented Trial-Data Standards Across EU Study Sites
4.4 Regulatory Landscape
4.5 Porter's Five Forces Analysis
4.5.1 Threat of New Entrants
4.5.2 Bargaining Power of Buyers/-Sponsors
4.5.3 Bargaining Power of CRO / Tech Suppliers
4.5.4 Threat of Substitutes
4.5.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Phase
5.1.1 Phase I
5.1.2 Phase II
5.1.3 Phase III
5.1.4 Phase IV
5.2 By Study Design
5.2.1 Interventional / Treatment Studies
5.2.2 Observational Studies
5.2.3 Expanded Access Studies
5.3 By Service Type
5.3.1 Protocol Design & Feasibility
5.3.2 Site Identification & Start-up
5.3.3 Regulatory Submission & Approval
5.3.4 Clinical Trial Monitoring
5.3.5 Data Management & Biostatistics
5.3.6 Medical Writing
5.3.7 Other Service Types
5.4 By Therapeutic Area
5.4.1 Oncology
5.4.2 Cardiovascular
5.4.3 Neurology
5.4.4 Infectious Diseases
5.4.5 Metabolic Disorders (Diabetes, Obesity)
5.4.6 Immunology / Autoimmune
5.4.7 Other Therapeutic Areas
5.5 By Sponsor Type
5.5.1 Pharmaceutical & Biopharmaceutical Companies
5.5.2 Medical Device Companies
5.5.3 Academic & Research Institutes
5.5.4 Government & Non-profit Organizations
5.6 Geography
5.6.1 Germany
5.6.2 United Kingdom
5.6.3 France
5.6.4 Italy
5.6.5 Spain
5.6.6 Rest of Europe
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products & Services, Recent Developments)
6.3.1 IQVIA
6.3.2 Parexel International (MA) Corporation
6.3.3 ICON plc
6.3.4 Thermo Fisher Scientific Inc.
6.3.5 Laboratory Corporation of America Holdings
6.3.6 Syneos Health
6.3.7 Medpace Holdings
6.3.8 Charles River Laboratories
6.3.9 Clinipace
6.3.10 Eli Lilly
6.3.11 Pfizer Inc.
6.3.12 F. Hoffmann-La Roche
6.3.13 Sanofi
6.3.14 Novo Nordisk
6.3.15 AstraZeneca
6.3.16 Boehringer Ingelheim
6.3.17 Novartis
6.3.18 Bayer AG
6.3.19 Johnson & Johnson (Janssen)
6.3.20 Merck KGaA
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security